Gilead acquiring cancer and inflammation company Calistoga Pharmaceuticals for $375M in upfront cash and $225M in milestones payment.

Calistoga Pharmaceuticals Inc.

U.S. / Private Biopharma

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Gilead Sciences Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Completed

Sample

01/01/2009

announced

01/01/2009

completed